Study shows consistent efficacy of Paxlovid regardless of age, number of vaccinations, comorbidities

In a recent study posted to the medRxiv* preprint server, researchers in Canada evaluated nirmatrelvir and ritonavir (Paxlovid) effectiveness against severe coronavirus disease 2019 (COVID-19) during the dominance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) and Omicron sub-VOCs in Canada.